Platelet News and Research

RSS

Recent clinical study offers hope for potential Parkinson's disease therapies

Researchers have long sought treatments that can slow the progression of Parkinson's disease. Current treatments have for decades been only symptomatic in nature, supplying the neurotransmitter dopamine, which the dying nerve cells can no longer produce.

18 Feb 2015

Eliglustat drug improves liver, spleen size and hemoglobin level in adults with Gaucher disease type 1

Among previously untreated adults with Gaucher disease type 1, a genetic disease in which there is improper metabolism due to a defect in an enzyme, treatment with the drug eliglustat resulted in significant improvements in liver and spleen size hemoglobin level, and platelet count, according to a study in the February 17 issue of JAMA.

18 Feb 2015

Cumberland initiates clinical development of Boxaban (ifetroban) oral capsule for AERD treatment

Cumberland Pharmaceuticals Inc. today announced an expansion of its pipeline with a new Phase II development program. The Company has initiated the clinical development of Boxaban (ifetroban) oral capsule for the treatment of aspirin-exacerbated respiratory disease (AERD).

11 Feb 2015

Common treatment not effective in reducing risk of death for patients with TBI

More than 1.7 million people in the U.S. alone suffer a traumatic brain injury (TBI) every year, often resulting in permanent disabilities or death. Up to half of these patients will experience progression of bleeding inside or around the brain, the occurrence of which is associated with an increased risk of death.

28 Jan 2015

Platelet transfusion treatment increases death in people with certain rare blood cell disorders

People hospitalized with certain rare blood cell disorders frequently receive a treatment that is associated with a two- to fivefold increase in death, according to a new study that reviewed hospital records nationwide. The study authors recommend that for these rare disorders, doctors should administer the treatment, a platelet transfusion, only in exceptional circumstances.

14 Jan 2015

Blast phase characteristics differ in TKI-, non-TKI–treated CML patients

Features of the blast phase, such as blast cell morphology and accompanying cytogenetic changes, vary between chronic myeloid leukaemia patients who received tyrosine kinase inhibitor therapy and those treated in the pre-TKI era, research shows.

12 Jan 2015

Arcturus to exhibit new mRNA therapeutics pipeline at two healthcare conferences

Arcturus Therapeutics Inc., developing the 'next wave' of RNA medicines, today announced that Joseph Payne, President and Chief Executive Officer, is scheduled to present a corporate overview, including the company's new messenger RNA (mRNA) therapeutics pipeline, at two upcoming healthcare conferences.

7 Jan 2015

Deoxygenated hemoglobin triggers conversion of nitrite to nitric oxide

Understanding how nitrite can improve conditions such as hypertension, heart attack and stroke has been the object of worldwide research studies. New research from Wake Forest University has potentially moved the science one step closer to this goal.

14 Dec 2014

Nivolumab drug highly effective for Hodgkin's lymphoma

A phase I clinical trial of nivolumab found that the immune-boosting drug is a highly effective therapy for Hodgkin's lymphoma. The multi-institution study, led by Mayo Clinic, indicated that the drug was safe and led to an 87 percent response rate in patients who had failed on other treatments.

7 Dec 2014

Platelet-like nanoparticles mimic human body's coagulation process

Stanching the free flow of blood from an injury remains a holy grail of clinical medicine. Controlling blood flow is a primary concern and first line of defense for patients and medical staff in many situations, from traumatic injury to illness to surgery.

13 Nov 2014

Rigel Pharmaceuticals reports net loss of $20.9 million for third quarter of 2014

Rigel Pharmaceuticals, Inc. today reported financial results for the third quarter and nine months ended September 30, 2014.

4 Nov 2014

Boehringer Ingelheim's OFEV (nintedanib) capsules receive FDA approval for IPF treatment

Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration approved OFEV (nintedanib) capsules for oral use for the treatment of idiopathic pulmonary fibrosis (IPF).

15 Oct 2014

Mental stress affects women's hearts more than men's

Researchers have known for decades that stress contributes to heart disease. But a new analysis by researchers at Duke Medicine shows mental stress may tax women's hearts more than men's.

14 Oct 2014

Men and women have different cardiovascular, psychological reactions to mental stress

Men and women have different cardiovascular and psychological reactions to mental stress, according to a study of men and women who were already being treated for heart disease.

13 Oct 2014

NCCN ORP awards four research grants to advance development of nintedanib

The National Comprehensive Cancer Network Oncology Research Program has awarded four grants to investigators to evaluate and define the clinical effectiveness of the investigational compound nintedanib (BIBF 1120) in non-small cell lung, colorectal, and gastrointestinal cancers.

25 Sep 2014

Synthetic platelet-like particles could augment natural blood clotting for treatment of traumatic injuries

A new class of synthetic platelet-like particles could augment natural blood clotting for the emergency treatment of traumatic injuries - and potentially offer doctors a new option for curbing surgical bleeding and addressing certain blood clotting disorders without the need for transfusions of natural platelets.

8 Sep 2014

Chemical engineers devise new implantable tissue scaffold coated with bone growth factors

MIT chemical engineers have devised a new implantable tissue scaffold coated with bone growth factors that are released slowly over a few weeks. When applied to bone injuries or defects, this coated scaffold induces the body to rapidly form new bone that looks and behaves just like the original tissue.

20 Aug 2014

Black and Hispanic SLE patients are more likely to be readmitted than white patients

A new study reveals that one in six patients with systemic lupus erythematosus (SLE) is readmitted to the hospital within 30 days of being discharged.

11 Aug 2014

CTI BioPharma's pacritinib granted FDA Fast Track designation for treatment of myelofibrosis

CTI BioPharma Corp. announced today that pacritinib has been granted Fast Track designation by the U.S. Food and Drug Administration for the treatment of intermediate and high risk myelofibrosis, including but not limited to patients with disease related thrombocytopenia, patients experiencing treatment emergent thrombocytopenia on other JAK2 therapy or patients who are intolerant to or whose symptoms are sub-optimally managed on other JAK2 therapy.

7 Aug 2014

Experts explain pros and cons of over-the-counter enzymes

Enzyme supplements available without a prescription are becoming increasingly popular, but should everyone add them to their shopping list? Brent Bauer, M.D., director of the Mayo Clinic Complementary and Integrative Medicine Program, is co-author of a new paper in the medical journal Mayo Clinic Proceedings on the pros and cons of over-the-counter enzymes.

5 Aug 2014